Thomas Mangner Selected Research

6-(trifluoroacetamido)-1-hexanoicanilide

1/2022	Spatial and temporal dynamics of HDACs class IIa following mild traumatic brain injury in adult rats.
1/2019	Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Thomas Mangner Research Topics

Disease

3	Neoplasms (Cancer) 01/2020 - 01/2018
3	Glioma (Gliomas) 01/2020 - 01/2018
1	Brain Concussion (Cerebral Concussion) 01/2022
1	Epilepsy (Aura) 04/2002
1	Alternating hemiplegia of childhood 04/2002
1	Migraine Disorders (Migraine) 04/2002

Drug/Important Bio-Agent (IBA)

2	6-(trifluoroacetamido)-1-hexanoicanilideIBA 01/2022 - 01/2019
2	Sirtuin 1IBA 01/2020 - 01/2019
2	6- chloro- 2,3,4,9- tetrahydro- 1H- carbazole- 1- carboxamideIBA 01/2020 - 01/2019
2	MC1568IBA 01/2020 - 01/2019
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2020
1	EnzymesIBA 01/2019
1	Sirtuin 2IBA 01/2018
1	Serotonin (5 Hydroxytryptamine)IBA 04/2002
1	Tryptophan (L-Tryptophan)FDA Link 04/2002
1	Neurotransmitter Agents (Neurotransmitter)IBA 04/2002

Therapy/Procedure

1	Radiotherapy 01/2019
1	Intravenous Administration 01/2018